The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation.
Hematocrit and blood ferritin were assayed in 43 women using a levonorgestrel intrauterine device (LevoNg-IUD), 49 using the Copper T-380 Ag (T-Cu 380 Ag), 27 using the Lippes loop and 30 non-IUD users as controls. The mean duration of use was 41 months for the three IUD groups. Women not using IUDs and with similar age, parity, years of schooling and family income as users had a normal mean hematocrit and ferritin, but 30% had low hematocrit (below 38%) and 43% had low ferritin (below 11 ng/ml). After prolonged use of the IUDs, 26% of users of Lippes loop, 22% of users of T-Cu 380 Ag and only 2% of users of LevoNg-IUD had subnormal hematocrit; 70%, 55% and 14%, respectively, had low ferritin. Thus, in a population with high incidence of anemia, the use of LevoNg-IUD appears to reduce the proportion of women with clinical anemia and with depletion of their iron store.
D000328:Adult; D000747:Anemia, Hypochromic / Q000097:blood* / Q000175:diagnosis; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D005260:Female; D005293:Ferritins / Q000097:blood; D006400:Hematocrit; D006801:Humans; D007434:Intrauterine Devices; D016912:Levonorgestrel; D008875:Middle Aged; D009644:Norgestrel / Q000008:administration & dosage*
D003271:Contraceptive Agents, Female; D009644:Norgestrel; D016912:Levonorgestrel; D005293:Ferritins